![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Interferon- and Ribavirin-Free Regimen of ABT-450/r and ABT-267 in Treatment-Experienced Japanese Patients Infected With HCV Genotype 1b or Genotype 2
|
|
|
Reported by Jules Levin
Presented at the Asian Pacific Association on for the Study of the Liver, 12-15 March 2014, Brisbane, Australia
K Chayama1, K Notsumata2, M Kurosaki3, K Sato4, L Rodrigues Jr5, C Setze5, P Badri5, T Pilot-Maias5, RA Vilchez5, H Kumada6
1Hiroshima University, Higashi-Hiroshima, Japan; 2Fukuiken Saiseikai Hospital, Fukui, Japan; 3Musashino Red Cross Hospital, Musashino, Japan; 4Gunma University Hospital, Maebashi, Japan;
5AbbVie Inc., North Chicago, Illinois, United States; 6Toranomon Hospital, Tokyo, Japan
![APASL1.gif](../images/031714/031714-12/APASL1.gif)
![APASL2.gif](../images/031714/031714-12/APASL2.gif)
![APASL3.gif](../images/031714/031714-12/APASL3.gif)
![APASL4.gif](../images/031714/031714-12/APASL4.gif)
![APASL5.gif](../images/031714/031714-12/APASL5.gif)
![APASL6.gif](../images/031714/031714-12/APASL6.gif)
![APASL7.gif](../images/031714/031714-12/APASL7.gif)
![APASL8.gif](../images/031714/031714-12/APASL8.gif)
![APASL9.gif](../images/031714/031714-12/APASL9.gif)
![APASL10.gif](../images/031714/031714-12/APASL10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|